The healthcare AI race has a new benchmark winner, and it is not Anthropic, OpenAI, or any of the frontier model labs spending billions on general-purpose intelligence. It is Doximity, a digital platform for U.S. physicians that entered Friday, August 7, 2026, with its stock sitting roughly 50% below where it opened 2026.
By the close, that story looked very different.
What Actually Happened Friday
The earnings were solid, not spectacular. Revenue climbed 7% year over year to $156.6 million. Earnings came in at 29 cents per share. On those numbers alone, a 30%-plus gain would have been hard to justify.
The move was not about the quarterly income statement. It was about a unit economics disclosure CEO Jeff Tangney delivered on the earnings call Thursday evening: the company said it is earning more than 10 times per search in revenue than it costs.
That one disclosure reframed the entire investment debate around Doximity’s AI pivot. Over time, management expects AI costs to decrease as models become more efficient. The unit economics, in other words, could improve from an already extraordinary baseline.
Market Temperature
Context matters here. Doximity’s market value was about $3.7 billion heading into the results, and the stock was down about 50% year to date before earnings. The compression happened for reasons: softer pharma advertising budgets, a CFO transition earlier in the year, and persistent skepticism about whether the company’s AI investments would ever convert to revenue.
Wall Street had already punished the stock repeatedly. Bank of America had downgraded Doximity to Underperform, cutting its price target to $20 from $38, citing AI execution risks and concerns that heavier investment spending could weigh on margins. Short sellers agreed. Short interest was in the mid-teens as a percentage of float in mid-July, and as those short sellers were forced to unwind their positions, it likely added fuel to the surge.
The mechanical amplification was real. When a heavily shorted stock rises sharply after positive news, traders betting against the company are often forced to buy shares to close their positions, and that buying pressure likely accelerated Friday’s gains. But the squeeze alone does not explain a 33% close after an enormous premarket spike. The fundamentals had to deliver something real first.
Company Introduction: Medicine’s Professional Network, Rebuilt for AI
Doximity’s network members include more than 85% of U.S. physicians across all specialties and practice areas. That distribution moat is not new. What is new is how the company is monetizing it.
Best known as a professional networking platform for physicians, it now sells an AI assistant called Ask that helps doctors summarize patient notes, check drug interactions, and draft documentation. Every answer runs through a physician review layer called PeerCheck, where physicians review AI output. That physician-in-the-loop architecture is not just a safety feature. It is a competitive moat in an era when hospital liability committees are the gatekeepers to enterprise AI contracts.
Data-Driven Deep Dive
Engagement is running well ahead of monetization. Workflow-active prescribers surged more than 30% from a year ago, while AI Search queries jumped over 25% sequentially. That gap between engagement and revenue is, counterintuitively, the bullish case. The conversion has barely started.
Doximity recognized no AI Search revenue during fiscal Q1. It onboarded more than two dozen programs. The company has said more than 100 leading health systems have purchased its AI suite. Revenue from those relationships is expected to begin flowing later, as the company scales commercialization.
On the pharma side, the company has reported that its cohort of customers generating more than $500,000 in trailing 12-month subscription revenue has been in the mid-120s. That customer count is the foundation for the AI Search commercial layer now being built on top.
The balance sheet is clean. The company continues to report a net cash position with no debt on its balance sheet, and it has continued to repurchase shares while investing in AI.
Guidance moved up, not down. For the full fiscal year 2027, Doximity raised revenue guidance to $671 million to $681 million, higher than the prior range of $664 million to $676 million. Management expects stronger growth later in the fiscal year as AI Search revenue builds. The EBITDA range was trimmed slightly, a deliberate trade. CFO Matt Sonefeldt noted that AI Search is expected to be accretive to margins in fiscal 2028 and beyond.
Strategic Insight: The Clinical AI Benchmark Nobody Saw Coming
The profit margin disclosure was the spark. The clinical benchmark is the deeper story.
The NOHARM study, conducted by ARISE, a clinical AI research team, evaluated how AI models perform when researchers prompted them with simulated patient cases. Doximity has said Doximity Ask ranked first among the systems evaluated in that work.
Tangney highlighted a gap in error rates between Doximity Ask and a leading general-purpose model in the benchmark. That kind of difference matters to hospital procurement teams. This validation is crucial for hospital AI steering committees concerned about liability and patient data privacy, positioning Doximity to win enterprise contracts as the market shifts from an anything-goes environment to an enterprise-driven, accountability-focused model.
CEO Tangney attributes the performance to the company’s built-in clinical references and its physician review process that continuously refines AI outputs. That network of physician oversight is not something any general-purpose model lab can replicate quickly. It has been built over years of being the platform where U.S. doctors actually work.
Tangney said AI Search is helping the company engage with senior executives at pharmaceutical companies and expanding its total addressable market in healthcare. That is the sentence that moved the stock. Doximity had positioned itself as a physician engagement platform. The AI search layer is repositioning it as a pharmaceutical marketing channel with reach that competitors cannot match.
Risks Section
The optimism deserves scrutiny. Three risks are worth naming directly.
The NOHARM benchmark is contested. OpenEvidence CEO Daniel Nadler pushed back on the methodology after the results were announced, arguing that the study’s design was flawed and expressing doubt the study would pass peer review. Doximity’s clinical AI superiority claim rests partly on a benchmark that has not yet cleared that bar.
Revenue timing is back-loaded. The full-year revenue guidance midpoint implies roughly mid-single-digit growth, and near-term quarterly growth has been expected to be modest. Investors buying the AI story today are pricing in later-quarter delivery. If that conversion slips, the stock has limited cushion at current levels.
Free cash flow compressed sharply. The company has reported a year-over-year decline in operating cash flow and free cash flow in fiscal Q1 as it invested more heavily. Investing aggressively into AI is the explicit rationale, but the margin compression is real while the revenue payoff remains future-tense.
Big Picture: Healthcare AI Is Not a Single-Winner Market
Doximity’s Friday move happened inside a broader shift. Healthcare AI procurement is moving from pilot programs to enterprise-scale commitments, and the selection criteria are changing. Safety, liability protection, and physician trust are displacing raw benchmark scores on multiple-choice medical exams.
States have moved in the opposite direction from the federal level, passing a wave of new laws in 2026 governing AI use, many requiring human oversight before AI-assisted decisions reach a patient. That regulatory direction plays directly into Doximity’s PeerCheck architecture. A platform where physicians are already embedded in the review loop is structurally advantaged relative to tools that require health systems to build that oversight layer from scratch.
The pharma angle compounds the opportunity. AI Search is helping Doximity engage with senior executives at pharmaceutical companies and expanding its total addressable market in healthcare. Traditional pharma digital marketing runs through search engines and media networks. A platform reaching 85% of U.S. physicians, with AI-powered targeting at the point of prescribing intent, is a fundamentally different channel. That is the market Tangney described as a genuine surprise.
Final Thought
The stock was up sharply at one point Friday. It closed about 33% higher. The premarket spike was even larger. None of those numbers are the point.
The point is that Doximity entered the week as a beaten-down physician networking platform with an unproven AI bet and a stock price that implied the bet would not pay off. It exited the week having disclosed unit economics that suggest the bet is paying off faster and more profitably than even management expected.
Michael Cherny of Leerink Partners said the early success of the AI search initiative strengthens confidence that Doximity’s increased investment in AI will ultimately support attractive long-term profit margins. That view may now need to be revisited by analysts who were still sitting on the fence heading into results.
The revenue conversion is the next test. A more significant inflection is expected later as AI Search contracts begin to turn into recognized revenue. Until then, the stock has priced in a significant amount of faith. Whether that faith is well-placed depends entirely on how many of those signed health-system clients start generating subscription revenue in the back half of fiscal 2027.
Worth watching closely.
Subject Line
Doximity Jumped 33%. Here’s the Real Reason.
Preheader
A 10x unit economics disclosure and a clinical AI benchmark win just rewrote the investment case for a stock that was down about 50% this year.
Meta Description
Doximity stock surged about 33% on August 7, 2026, after CEO Jeff Tangney disclosed that its AI Search product earns more than 10 times its cost per query. Here is what the numbers, the benchmark win, and the risks actually mean for investors.
Disclaimer
This editorial is for informational purposes only and does not constitute financial advice, a solicitation, or a recommendation to buy or sell any security. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. Always conduct your own due diligence or consult a licensed financial advisor before making any investment decisions.